Enteroendocrine Cells Before and After Sleeve Gastrectomy

University Hospital, Basel, Switzerland40 enrolled

Overview

Morbidly obese patients exhibit impaired secretion of satiation hormones which may contribute to the development of obesity. Bariatric surgery is associated with weight loss and dramatic increase in the secretion of satiation hormones, but the underlying mechanism remains unknown. The investigator's goal is therefore to examine patients before and after sleeve gastrectomy and compare findings to lean controls.

Morbidly obese patients exhibit impaired secretion of satiation hormones cholecystokinin (CCK), glucagon-like peptide 1 (GLP-1) and peptide YY (PYY), which may contribute to the development of obesity. Bariatric surgery is associated with weight loss and dramatic increase in the secretion of satiation hormones, but the underlying mechanism remains unknown. A better understanding of mechanisms involved will assist in development of non-invasive therapeutic strategies. The investigator's goal is therefore to examine patients before and after sleeve gastrectomy and compare findings to lean controls. Gastric and intestinal mucosa will be collected by endoscopy from morbidly obese subjects before and 3 months after sleeve gastrectomy. In Addition, lean controls will be examined. Expression of various gut peptides will be assessed by immunohistochemistry and quantitative polymerase chain reaction (PCR).

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Obesity

Interventions

sleeve gastrectomyPROCEDURE

Sleeve gastrectomy is an established form of bariatric (weight reducing) surgery, where the greater curvature of the stomach is removed.

no interventionOTHER

lean control group

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: Morbidly obese patients scheduled for sleeve gastrectomy * BMI \> 35 kg/m2 * Age: \> 18-65 years Lean, healthy controls * BMI \> 18 and \< 28kg/m2 * Age: \>18-40 years Exclusion Criteria: * Bleeding diathesis * Previous surgery on the gastrointestinal tract (appendectomy acceptable)

Locations (1)

University Hospital Basel

Basel, Switzerland

Outcomes

Primary Outcomes

Quantification of the enteroendocrine cell population

Expression of enteroendocrine cell population possessing chromogranin A, ghrelin, CCK, PYY, GLP-1 and GLP-2 by immunohistochemistry and quantitative PCR.

Time frame: within 3 months after surgery

Secondary Outcomes

Determination of tissue morphology (crypt depth, villus height)

Morphometric analysis

Time frame: within 3 months after surgery

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.